Therefore, whether the TME of EGFR+/c-MET+ mutant NSCLC, such as EGFR-TKI resistant NSCLC acquired c-MET amplification, is different from the EGFR+/c-MET− mutant NSCLC, and the response rates to PD-1/PD-L1 therapies require further investigation. The gene discussed is MET; the disease is non-small cell lung carcinoma.